Back to Search Start Over

Prevalence, Characteristics, and Outcomes of COVID-19-Associated Acute Myocarditis

Authors :
Enrico Ammirati
Laura Lupi
Matteo Palazzini
Nicholas S. Hendren
Justin L. Grodin
Carlo V. Cannistraci
Matthieu Schmidt
Guillaume Hekimian
Giovanni Peretto
Thomas Bochaton
Ahmad Hayek
Nicolas Piriou
Sergio Leonardi
Stefania Guida
Annalisa Turco
Simone Sala
Aitor Uribarri
Caroline M. Van de Heyning
Massimo Mapelli
Jeness Campodonico
Patrizia Pedrotti
Maria Isabel Barrionuevo Sánchez
Albert Ariza Sole
Marco Marini
Maria Vittoria Matassini
Mickael Vourc’h
Antonio Cannatà
Daniel I. Bromage
Daniele Briguglia
Jorge Salamanca
Pablo Diez-Villanueva
Jukka Lehtonen
Florent Huang
Stéphanie Russel
Francesco Soriano
Fabrizio Turrini
Manlio Cipriani
Manuela Bramerio
Mattia Di Pasquale
Aurelia Grosu
Michele Senni
Davide Farina
Piergiuseppe Agostoni
Stefania Rizzo
Monica De Gaspari
Francesca Marzo
Jason M. Duran
Eric D. Adler
Cristina Giannattasio
Cristina Basso
Theresa McDonagh
Mathieu Kerneis
Alain Combes
Paolo G. Camici
James A. de Lemos
Marco Metra
Ammirati, E
Lupi, L
Palazzini, M
Hendren, N
Grodin, J
Cannistraci, C
Schmidt, M
Hekimian, G
Peretto, G
Bochaton, T
Hayek, A
Piriou, N
Leonardi, S
Guida, S
Turco, A
Sala, S
Uribarri, A
Van De Heyning, C
Mapelli, M
Campodonico, J
Pedrotti, P
Barrionuevo Sanchez, M
Ariza Sole, A
Marini, M
Matassini, M
Vourc'H, M
Cannata, A
Bromage, D
Briguglia, D
Salamanca, J
Diez-Villanueva, P
Lehtonen, J
Huang, F
Russel, S
Soriano, F
Turrini, F
Cipriani, M
Bramerio, M
Di Pasquale, M
Grosu, A
Senni, M
Farina, D
Agostoni, P
Rizzo, S
De Gaspari, M
Marzo, F
Duran, J
Adler, E
Giannattasio, C
Basso, C
Mcdonagh, T
Kerneis, M
Combes, A
Camici, P
De Lemos, J
Metra, M
CarMeN, laboratoire
Niguarda Hospital [Milan, Italy]
University of Brescia
University of Texas Southwestern Medical Center [Dallas]
Tsinghua University [Beijing] (THU)
Center for Systems Biology Dresden [Dresden, Germany] (CSBD)
Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN)
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN)
CHU Pitié-Salpêtrière [AP-HP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Universita Vita Salute San Raffaele = Vita-Salute San Raffaele University [Milan, Italie] (UniSR)
Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN)
Université Claude Bernard Lyon 1 (UCBL)
Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)
Hospices Civils de Lyon (HCL)
Université de Lyon
unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX)
Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE)
Nantes Université - pôle Santé
Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé
Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)
Università degli Studi di Pavia = University of Pavia (UNIPV)
Fondazione IRCCS Policlinico San Matteo [Pavia]
Hospital Clinico Universitario de Valladolid [Castilla y León, Spain] (HCUV)
Instituto de Salud Carlos III [Madrid] (ISC)
University of Antwerp (UA)
Università degli Studi di Milano = University of Milan (UNIMI)
IRCCS Istituto Nazionale dei Tumori [Milano]
Bellvitge University Hospital [Barcelona, Spain]
Presidio Ospedaliero 'G. Salesi' AN = Ancona Hospital Salesi [Ancona, Italy] (POGSA-AHS)
Hôpital Guillaume-et-René-Laennec [Saint-Herblain]
Centre hospitalier universitaire de Nantes (CHU Nantes)
Thérapeutiques cliniques et expérimentales des infections (EA 3826) (EA 3826)
Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE)
King‘s College London
King's College Hospital (KCH)
Mater Domini Humanitas Hospital [Castellanza, Italy] (MD2H)
Hospital Universitario de La Princesa
Helsinki University Hospital [Finland] (HUS)
Hôpital Foch [Suresnes]
Ospedale Civile di Baggiovara [Modena, Italy] (OCB)
Hospital Papa Giovanni XXIII (Hosp P Giovanni XXIII)
Azienda Ospedale Università di Padova = Hospital-University of Padua (AOUP)
Ospedale 'Infermi' di Rimini [Rimini, Italy] (OIR)
University of California [San Diego] (UC San Diego)
University of California (UC)
Università degli Studi di Milano-Bicocca = University of Milano-Bicocca (UNIMIB)
Source :
Circulation, Circulation, 2022, 145 (15), pp.1123-1139. ⟨10.1161/circulationaha.121.056817⟩
Publication Year :
2022

Abstract

Background: Acute myocarditis (AM) is thought to be a rare cardiovascular complication of COVID-19, although minimal data are available beyond case reports. We aim to report the prevalence, baseline characteristics, in-hospital management, and outcomes for patients with COVID-19–associated AM on the basis of a retrospective cohort from 23 hospitals in the United States and Europe. Methods: A total of 112 patients with suspected AM from 56 963 hospitalized patients with COVID-19 were evaluated between February 1, 2020, and April 30, 2021. Inclusion criteria were hospitalization for COVID-19 and a diagnosis of AM on the basis of endomyocardial biopsy or increased troponin level plus typical signs of AM on cardiac magnetic resonance imaging. We identified 97 patients with possible AM, and among them, 54 patients with definite/probable AM supported by endomyocardial biopsy in 17 (31.5%) patients or magnetic resonance imaging in 50 (92.6%). We analyzed patient characteristics, treatments, and outcomes among all COVID-19–associated AM. Results: AM prevalence among hospitalized patients with COVID-19 was 2.4 per 1000 hospitalizations considering definite/probable and 4.1 per 1000 considering also possible AM. The median age of definite/probable cases was 38 years, and 38.9% were female. On admission, chest pain and dyspnea were the most frequent symptoms (55.5% and 53.7%, respectively). Thirty-one cases (57.4%) occurred in the absence of COVID-19–associated pneumonia. Twenty-one (38.9%) had a fulminant presentation requiring inotropic support or temporary mechanical circulatory support. The composite of in-hospital mortality or temporary mechanical circulatory support occurred in 20.4%. At 120 days, estimated mortality was 6.6%, 15.1% in patients with associated pneumonia versus 0% in patients without pneumonia ( P =0.044). During hospitalization, left ventricular ejection fraction, assessed by echocardiography, improved from a median of 40% on admission to 55% at discharge (n=47; P Conclusions: AM occurrence is estimated between 2.4 and 4.1 out of 1000 patients hospitalized for COVID-19. The majority of AM occurs in the absence of pneumonia and is often complicated by hemodynamic instability. AM is a rare complication in patients hospitalized for COVID-19, with an outcome that differs on the basis of the presence of concomitant pneumonia.

Details

Language :
English
ISSN :
00097322 and 15244539
Database :
OpenAIRE
Journal :
Circulation, Circulation, 2022, 145 (15), pp.1123-1139. ⟨10.1161/circulationaha.121.056817⟩
Accession number :
edsair.doi.dedup.....8c53f251d632e0d45f895238db4a4f78